Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,201.76 USD
+2.39 (0.20%)
Updated Aug 27, 2024 04:00 PM ET
After-Market: $1,201.97 +0.21 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1,201.76 USD
+2.39 (0.20%)
Updated Aug 27, 2024 04:00 PM ET
After-Market: $1,201.97 +0.21 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Zacks News
Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma
by Zacks Equity Research
REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).
HRMY or REGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRMY vs. REGN: Which Stock Is the Better Value Option?
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
by Zacks Equity Research
Alnylam's (ALNY) Amvuttra and Givlaari sales continue to boost revenues. However, its reliance on collaboration partners and stiff competition remain concerns.
Biotech Stock Roundup: CRL for REGN, GILD's Drug Approval, LQDA Down on News
by Ekta Bagri
Bigwigs Regeneron (REGN) and Gilead Sciences (GILD) are in the spotlight following regulatory updates and drug approval, respectively.
Regeneron (REGN) Gets CRL From FDA for Multiple Myeloma Drug
by Zacks Equity Research
Regeneron (REGN) suffers a delay in obtaining FDA approval of linvoseltamab for the treatment of relapsed/refractory multiple myeloma.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
HRMY vs. REGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRMY vs. REGN: Which Stock Is the Better Value Option?
Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Intellia's (NTLA) second-quarter 2024 earnings and revenues lag estimates. The company provides developmental and regulatory updates on its pipeline candidates.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Bayer (BAYRY) Q2 Earnings In Line, Nubeqa, Kerendia Boost Sales
by Zacks Equity Research
Bayer's (BAYRY) second-quarter earnings match the consensus estimate. Sales gain from the Pharmaceutical business' strong performance.
Regeneron (REGN) Q2 Earnings Gain From Eylea HD, Dupixent
by Zacks Equity Research
Regeneron's (REGN) decent second-quarter results can be attributed to strong uptake of Eylea HD sales and high Dupixent profits, even though lead drug Eylea is under pressure.
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues
by Zacks Equity Research
Alnylam (ALNY) gains 13% on upbeat second-quarter results, beating both earnings and revenue estimates, primarily driven by higher collaboration revenues from Regeneron and strong Amvuttra sales.
Ultragenyx (RARE) Q2 Loss Narrower Than Expected, Revenues Up
by Zacks Equity Research
Ultragenyx (RARE) reports encouraging second-quarter 2024 results, beating both earnings and revenue estimates driven by the year-over-year increase of Crysvita and Dojolvi sales.
Defensive Sectors Breakout: 3 Stocks to Buy Now for Protection
by Ethan Feller
AvalonBay Communities, Regeneron Pharmaceuticals and Public Service Enterprise Group are all rallying as investors rotate into defensive sectors
Compared to Estimates, Regeneron (REGN) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Regeneron (REGN) Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales
by Zacks Equity Research
Regeneron (REGN) reports strong Q2 results, wherein both the top and bottom lines beat estimates due to higher Eylea HD and Libtayo sales and profits from Dupixent sales.
Regeneron (REGN) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 9.37% and 4.84%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
by Ekta Bagri
Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Regeneron and Optex Systems
by Zacks Equity Research
Goldman Sachs, RTX, Regeneron and Optex Systems are included in this Analyst Blog.
Top Analyst Reports for Goldman Sachs, RTX & Regeneron
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Goldman Sachs Group, Inc. (GS), RTX Corporation (RTX) and Regeneron Pharmaceuticals, Inc. (REGN), as well as a micro-cap stock Optex Systems Holdings, Inc (OPXS).
Countdown to Regeneron (REGN) Q2 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Intellia's (NTLA) second-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing candidates.